Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saquinavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saquinavir SCHEMBL1176566 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL13575784 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL1976548 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL20451344 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL8584255 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL8584252 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL6881 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL13953012 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL21683360 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| Saquinavir SCHEMBL29357501 | 1.00 | CYP3A4 (1.00) | CYP3A4ABCC4ABCB11ABCB1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11980613-B2 | Methods for reversing HIV latency using BAF complex modulating compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-05-14 | — | — | US | disclosed |
| US-11807852-B2 | Compositions and methods for reactivating latent immunodeficiency virus | THE J. DAVID GLADSTONE INSTITUTES (US) | 2023-11-07 | — | — | US | disclosed |
| US-11590110-B2 | Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220364119-A1 | COMPOSITIONS AND METHODS FOR TREATING AN IMMUNODEFICIENCY VIRUS INFECTION WITH A THERAPEUTIC INTERFERING PARTICLE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-17 | — | — | US | disclosed |
| US-20220193209-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS AND/OR TREATING IMMUNODEFICIENCY VIRUS INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-23 | — | — | US | disclosed |
| EP-3982996-A1 | COMPOSITIONS AND METHODS FOR TREATING AN IMMUNODEFICIENCY VIRUS INFECTION WITH A THERAPEUTIC INTERFERING PARTICLE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220090085-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807852-B2 | Compositions and methods for reactivating latent immunodeficiency virus | NSUN2, IRF3, DNMT3B | CYP3A4 4068/4885ABCC4 4161/4885ABCB11 4407/4885 |
| US-20220090085-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | NSUN2, IRF3, DNMT3B | CYP3A4 4068/4885ABCC4 4161/4885ABCB11 4407/4885 |
| US-20220193209-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS AND/OR TREATING IMMUNODEFICIENCY VIRUS INFECTION | HAVCR2, CD4, MAVS | CYP3A4 3109/4885ABCC4 3842/4885ABCB11 3927/4885 |
| US-11980613-B2 | Methods for reversing HIV latency using BAF complex modulating compounds | CHD1L, SMARCC1, CHD1 | CYP3A4 4332/4885ABCC4 1913/4885ABCB11 2229/4885 |
| US-11590110-B2 | Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor | GSK3B, GSK3A, GSKIP | CYP3A4 2605/4885ABCC4 4871/4885ABCB11 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.